Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
07/2003
07/02/2003EP0841916B1 Endothelin receptor antagonists
07/02/2003EP0782986B1 Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
07/02/2003EP0779810B1 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
07/02/2003EP0732875B1 Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
07/02/2003CN1427837A Ortho-substituted anthranilic acid amides and their use as medicaments
07/02/2003CN1427835A Stepwise Alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
07/02/2003CN1427826A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use
07/02/2003CN1427825A Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
07/02/2003CN1427717A Hydrophilic/lipophilic polymeric matrix dosage for mulation
07/02/2003CN1426812A Relaxation of Climacteric syndrome by using antisenility action of glossy ganoderma
07/02/2003CN1426799A 按摩液 Massage fluid
07/02/2003CN1426782A Tanshinone 11A used in preparing medicine for preventing and treating atherosclerosis
07/02/2003CN1113059C Pipeazino derivatives as neurokinin antagonists
07/02/2003CN1113057C Quinoline derivatives
07/02/2003CN1112923C Indazole carboxamides
07/02/2003CN1112921C Compositions containing micronized nebivolol
07/02/2003CN1112920C Aminotetralin derivative for therapy of cardiovascular diseases
07/01/2003US6586623 Thiol-based NAALADase inhibitors
07/01/2003US6586582 Human GABA receptor proteins and polynucleotides encoding the same
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586448 Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders
07/01/2003US6586446 Chemotaxic cytokine agonists or antagonists such as N(3-acetylphlenyl)-N'-(-2-((-3-((4-fluorophenyl)methyl)-8 -azabicyclo(3.2.1)oct-8-yl)methyl)-(2R)-1-cyclohexyl)urea, used as antiinflammatory agents for asthma or allergies
07/01/2003US6586445 Racemic mixtures of 1,2,3,4-tetra hydro-1-(4-methoxyphenyl)-3 -(4-phenyl-1H-imidazol-2-yl)-9H- pyrido(3,4-b)indole, which bind to somatostatin receptors and block sodium channel modulators; antidiabetic, antiinflammatory agents; diarrhea
07/01/2003US6586442 Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
07/01/2003US6586441 Adenosine receptor ligands and their use in the treatment of disease
07/01/2003US6586436 Serotonergic agents
07/01/2003US6586432 Neurokinin-1 receptor antagonists
07/01/2003US6586431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives
07/01/2003US6586424 Anticancer agents; anticholesterol agents
07/01/2003US6586423 Tyrosine kinase inhibitors
07/01/2003US6586422 Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine
07/01/2003US6586414 Treatment of cerebrovascular disease
07/01/2003US6586396 Subcutaneous administration of natriuretic peptide
07/01/2003US6586391 Method of ameliorating erectile dysfunction
07/01/2003US6586179 Human Eag2
07/01/2003US6586015 Use of Phyllanthus for treating chronic inflammatory and fibrotic processes
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
07/01/2003US6585995 Administering to a subject to inhibit a vaso-occlusive event an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level
06/2003
06/26/2003WO2003052106A1 Method of screening compounds
06/26/2003WO2003052100A1 Use of bard1 inhibitors for promoting cell survival
06/26/2003WO2003052095A2 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051905A2 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003051893A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051890A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051879A1 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051876A1 Pyrazolopyridine derivatives and medicinal use thereof
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051869A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051863A1 SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS
06/26/2003WO2003051855A1 N,n'-disubstituted piperazine compounds and the use of the same as analgesics
06/26/2003WO2003051851A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003WO2003051847A1 (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
06/26/2003WO2003051845A1 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051840A1 Pyrrolidine and piperidine derivates as nk1 antagonists
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051825A1 Human adam-10 inhibitors
06/26/2003WO2003051822A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051821A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051458A1 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051396A1 Treating vascular disease by inhibiting myeloid differentiation factor 88
06/26/2003WO2003051395A2 Edg-receptor agonist for the treatment of hypertension
06/26/2003WO2003051393A2 Enzymatic cleavable reagents for specific delivery to disease sites
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051372A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051362A2 Polymorphs of clopidogrel hydrogensulfate
06/26/2003WO2003051358A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003WO2003051353A1 Substituted beta-aminoalcohols used as medicaments
06/26/2003WO2003051347A1 Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
06/26/2003WO2003051346A2 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2003035678A3 Sperm factor sequences
06/26/2003WO2002065834A8 Novel formulations of carvedilol
06/26/2003WO2002058733A3 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
06/26/2003WO2002046385A3 Enzymes
06/26/2003WO2002016597A3 Lipid metabolism enzymes
06/26/2003US20030120080 Such as (2S)-2-((4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl) butanamide; antiepileptic agents; anticonvulsants
06/26/2003US20030120074 Cardioprotective phosphonates and malonates
06/26/2003US20030120070 Serotonin 5-HT1A and dopamin D2 receptor ligands
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030120038 Inhibitor of vascular endothelial cell growth factor
06/26/2003US20030119904 Solid, crystalline, non-hygroscopic acetyl L-carnitine fumarate; boiling point 0f 105-110 degrees c
06/26/2003US20030119893 Non-selective beta-blocker with a vasodilating component
06/26/2003US20030119873 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
06/26/2003US20030119869 1-(Piperidin-4-yl)benzimidazole or -triazole derivatives; agonists and antagonist for beta-chemokine (chemotactic cytokines) receptors; viricides; HIV; antiarthritic agents; atherosclerosis, psoriasis, antiallergens; multiple sclerosis
1 ... 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 ... 1595